Halozyme dips as Leerink downgrades on “marginal” Q3 upside
Seeking Alpha ·
Halozyme Therapeutics (HALO) stock falls as Leerink Partners downgrades the company noting that its Q3 2026 results only marginally exceeded consensus. Read more here.
Halozyme dips as Leerink downgrades on “marginal” Q3 upside
Halozyme Therapeutics (HALO) stock falls as Leerink Partners downgrades the company noting that its Q3 2026 results only marginally exceeded consensus. Read…
1 sources · 1 articles · updated 2026-11-06 16:13 UTC · business